三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

交易中 11-19 14:40:45

5.730

+0.040

+0.70%

最高5.750	最低5.670	成交量362.85万
今开5.690	昨收5.690	日振幅1.41%
总市值137.27亿	流通市值137.27亿	总股本23.96亿
成交额2,069万	换手率0.15%	流通股本23.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":5.73,"timestamp":1731998408826,"preClose":5.69,"halted":0,"volume":3628500,"delay":0,"floatShares":2395573912,"shares":2395573912,"eps":0.6830646,"marketStatus":"交易中","marketStatusCode":2,"change":0.04,"latestTime":"11-19 14:40:45","open":5.69,"high":5.75,"low":5.67,"amount":20694440,"amplitude":0.01406,"askPrice":5.73,"askSize":29000,"bidPrice":5.71,"bidSize":86500,"shortable":3,"etf":0,"ttmEps":0.732654337447663,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732003800000},"adr":0,"adjPreClose":5.69,"dividendRate":0.042631,"openAndCloseTimeList":[[1731979800000,1731988800000],[1731992400000,1732003200000]],"volumeRatio":0.370227,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2483736595","title":"三生制药获首席财务官何翔累计增持合共300万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483736595","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483736595?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:40","pubTimestamp":1731631200,"startTime":"0","endTime":"0","summary":"　　三生制药发布公告，近期接获公司首席财务官何翔的报告，其自2024年1月1日开始到本公告之日止，已通过集中竞价的方式，累计以平均价格每股股份约5.99港元增持公司合共300万股普通股，占已发行股份总数约0.12%。　　何翔向董事会确认，在增持公司股份时，不知悉任何有关公司的内幕信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxu3722593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxu3722593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1583","BK1593","01530"],"gpt_icon":0},{"id":"2483827243","title":"三生制药(01530.HK)首席财务官均价5.99元增持300万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483827243","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483827243?lang=zh_cn&edition=full","pubTime":"2024-11-15 01:37","pubTimestamp":1731605820,"startTime":"0","endTime":"0","summary":"三生制药(01530.HK) 公布，首席财务官何翔自今年1月1日起至今，通过集中竞价方式计增持300万股，占公司股本0.12%，每股平均价5.99元。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-14 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190627151657886_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190627151657886_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396781/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0},{"id":"2483087245","title":"三生制药CFO何翔增持300万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483087245","media":"财中社","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483087245?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:34","pubTimestamp":1731587691,"startTime":"0","endTime":"0","summary":"财中社11月14日电三生制药（01530）发布公告，首席财务官何翔于2024年1月1日至公告日，通过集中竞价方式增持本公司股份共计300万股，平均增持价格约为5.99港元，增持股份占已发行股份总数的0.12%。何翔表示，认为股份长期处于低估状态，基于对公司业务及前景的信心，未来可能会继续增持股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411143239995959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1161","BK1583","01530"],"gpt_icon":0},{"id":"2483819820","title":"三生制药(01530)：2024年“双十一”蔓迪®荣登多平台榜单榜首","url":"https://stock-news.laohu8.com/highlight/detail?id=2483819820","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483819820?lang=zh_cn&edition=full","pubTime":"2024-11-14 19:02","pubTimestamp":1731582142,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，公司旗下附属公司浙江三生蔓迪药业有限公司(三生蔓迪)在2024年“双十一”活动期间：于天猫平台主品牌蔓迪®荣登OTC品牌累计支付商品交易总额(GMV)榜单第一;于京东大药房核心产品蔓迪®生发泡沫剂荣获OTC单品榜单支付GMV第一;于抖音商城主品牌蔓迪®荣获医药健康品牌支付GMV榜单第一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0},{"id":"2483782727","title":"三生制药(01530)获首席财务官累计增持合共300万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483782727","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483782727?lang=zh_cn&edition=full","pubTime":"2024-11-14 19:01","pubTimestamp":1731582064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，近期接获公司首席财务官何翔的报告，其自2024年1月1日开始到本公告之日止，已通过集中竞价的方式，累计以平均价格每股股份约5.99港元增持公司合共300万股普通股，占已发行股份总数约0.12%。何翔向董事会表明，其认为股份长期处于低估状态，基于对公司业务及前景的长远信心，其将视乎市场情况并受限于适用法律及监管规定，进一步主动增持股份。何翔向董事会确认，在增持公司股份时，不知悉任何有关公司的内幕信息。本公告所涉及的增持为公司首席财务官的自愿行为。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01530","BK1593","BK1583"],"gpt_icon":0},{"id":"2483842210","title":"三生制药11月14日遭主力抛售535万元 环比增加698.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483842210","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483842210?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:17","pubTimestamp":1731572225,"startTime":"0","endTime":"0","summary":"11月14日, 三生制药股价跌0.51%，报收5.83元，成交金额5736万元，换手率0.41%，振幅2.90%，量比0.71。三生制药今日主力资金净流出535万元，连续3日净流出，上一交易日主力净流出67万元，今日环比增加698.51%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为64.71%，平均跌幅为2.53%。该股近5个交易日下跌2.82%，主力资金累计净流出1420万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出9046万元，其中净流出天数为16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161815a236c561&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161815a236c561&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1593","01530"],"gpt_icon":0},{"id":"2481117886","title":"【券商聚焦】招银国际：受益于海外降息以及国内宏观环境改善 医药作为高弹性行业有望跑赢市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2481117886","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481117886?lang=zh_cn&edition=full","pubTime":"2024-11-08 14:54","pubTimestamp":1731048893,"startTime":"0","endTime":"0","summary":"该行认为，宏观经济的表现与医保基金的收支、医疗健康消费息息相关。随着政策焦点转向刺激经济，该行认为医疗设备更新政策有望加速落地、创新药支持政策也有望在各地落地。CXO板块有望受益于海外研发需求复苏，《生物安全法案》的影响或将有限。该行推荐买入药明康德、百济神州、信达生物、联影医疗、巨子生物、三生制药、科伦博泰。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947380","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","LU0320764599.SGD","LU1046422090.SGD","LU0052750758.USD","02359","BK1583","BK1574","BK1576","LU2045819591.USD","HK0000934320.USD","LU1969619763.USD","BK1141","LU2328871848.SGD","02367","LU2242644610.SGD","BK1161","BK1207","01801","LU0196878994.USD","09939","BK1589","BK1515","BK1593","LU0708995583.HKD","06990","LU2488822045.USD","LU2125910500.SGD","01530"],"gpt_icon":0},{"id":"2481216949","title":"长江证券：首予三生制药(01530)“增持”评级 2024H1业绩较快增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2481216949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481216949?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:30","pubTimestamp":1730968257,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，长江证券发布研究报告称，首次覆盖三生制药，给予“增持”评级，预计2024-2026年公司实现营业收入90.90亿元、102.51亿元、117.11亿元，归母净利润21.73亿元、24.43亿元、27.27亿元，当前股价对应的PE倍数分别为6.9X、6.1X、5.5X。2024年H1公司业绩较快增长，核心产品渗透率提升。2024年H1，公司核心产品特比澳销售收入24.76亿元，同比增长22.6%，近三年收入增速均超过20%。截至2024年6月底，Winlevi继续蝉联美国市场处方量最大的痤疮药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000783","01530"],"gpt_icon":0},{"id":"2479713264","title":"南向资金10月30日净卖出三生制药234.95万股 连续7日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2479713264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479713264?lang=zh_cn&edition=full","pubTime":"2024-10-31 09:30","pubTimestamp":1730338212,"startTime":"0","endTime":"0","summary":"10月30日，南向资金减持三生制药234.95万股连续7日减持。截止当日收盘，港股通共持有三生制药67243.22万股，占流通股27.81%。三生制药近5个交易日下跌5.72%，港股通累计减持1611.80万股；近20个交易日下跌13.68%，港股通累计减持6787.45万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031093139ab877da1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031093139ab877da1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0},{"id":"2479494393","title":"南向资金10月28日净卖出三生制药136.10万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2479494393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479494393?lang=zh_cn&edition=full","pubTime":"2024-10-29 09:30","pubTimestamp":1730165414,"startTime":"0","endTime":"0","summary":"10月28日，南向资金减持三生制药136.10万股连续5日减持。截止当日收盘，港股通共持有三生制药67812.77万股，占流通股28.04%。三生制药近5个交易日下跌0.80%，港股通累计减持1481.50万股；近20个交易日上涨1.64%，港股通累计减持6446.25万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029093137a1f383c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029093137a1f383c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1593","01530","BK1583"],"gpt_icon":0},{"id":"2478617335","title":"三生制药10月28日遭主力抛售828万元 环比增加194.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478617335","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478617335?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:16","pubTimestamp":1730103403,"startTime":"0","endTime":"0","summary":"10月28日, 三生制药股价跌0.80%，报收6.20元，成交金额6551万元，换手率0.44%，振幅2.24%，量比0.88。三生制药今日主力资金净流出828万元，连续6日净流出，上一交易日主力净流出281万元，今日环比增加194.66%。该股近5个交易日下跌1.44%，主力资金累计净流出3115万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出5016万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028161711a1f146e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028161711a1f146e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1161","BK1583","01530"],"gpt_icon":0},{"id":"2478341991","title":"摩熵新药早报 | 华东医药前三季度营收314亿，净利润增长17%，重仓GLP-1!三生制药、宜联生物、翰森制药等出现重要进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2478341991","media":"药融云新药笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478341991?lang=zh_cn&edition=full","pubTime":"2024-10-26 08:00","pubTimestamp":1729900834,"startTime":"0","endTime":"0","summary":"其中第三季度华东医药实现营业收入105.13亿元，同比增长5.03%；实现归属于上市公司股东的净利润8.66亿元，同比增长14.71%。华东医药创新研发重点布局内分泌、自身免疫及肿瘤三大领域，目前创新产品管线已超70项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241026080637a1eb93d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241026080637a1eb93d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","01530"],"gpt_icon":0},{"id":"2478624180","title":"卫生署：“1+”审批机制11月起扩展至所有新药  体现“好药港用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2478624180","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478624180?lang=zh_cn&edition=full","pubTime":"2024-10-25 13:35","pubTimestamp":1729834500,"startTime":"0","endTime":"0","summary":"卫生署今日表示，按照《行政长官2024年施政报告》公布的措施，“1+”审批机制将于今年11月1日起扩展至所有新药，包括疫苗及先进疗法制品，体现“好药港用”。“1+”机制将于今年11月1日起扩展至适用于所有新药申请。卫生署已在有关网页公布扩展“1+”审批机制至所有新药的安排，并主动向持份者介绍关于“1+”机制的扩展及相关细节。首两款按“1+”机制获批治疗转移性结直肠癌的新药，已获纳入医管局药物名册的专用药物类别。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240409110313882_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240409110313882_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1391169/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["300760","LU0594300419.USD","LU0405327148.USD","LU2148510915.USD","LU2153592121.USD","LU1146622755.USD","LU0456842615.SGD","LU0405327494.USD","01530","LU2348774022.SGD","LU2424517915.HKD","SGXZ49509284.SGD","LU1934453819.USD","LU0594300179.USD","02367","LU1969619763.USD","LU0359202008.SGD","LU1688375341.USD","LU1794554557.SGD","BK1593","IE0005HP3H50.USD","LU1997245177.USD","LU1580142542.USD","LU2153591404.USD","LU0327786744.USD","SGXZ81163826.USD","LU2348773727.SGD","IE00B031HY20.USD","01801","LU0823426308.USD","LU0196878994.USD","BK1161","BK1207","IE00B031J352.USD","LU1979443071.USD","LU1720050803.USD","603259","LU1997245094.SGD","LU0605514214.HKD","BK1589","IE0008368742.USD","IE0031814852.USD","LU2488822045.USD","LU2328871848.SGD","LU0823426480.USD","BK0216","LU1820825898.SGD","BK1583","LU0572944931.SGD","06990"],"gpt_icon":0},{"id":"2478960648","title":"南向资金10月24日净卖出三生制药611.65万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2478960648","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478960648?lang=zh_cn&edition=full","pubTime":"2024-10-25 09:30","pubTimestamp":1729819813,"startTime":"0","endTime":"0","summary":"10月24日，南向资金减持三生制药611.65万股连续3日减持。截止当日收盘，港股通共持有三生制药68243.37万股，占流通股28.23%。港股通减持金额前五个股分别为中芯国际、香港交易所、中国人寿、中远海控、中国铝业。三生制药近5个交易日下跌0.80%，港股通累计减持1285.00万股；近20个交易日上涨5.62%，港股通累计减持6820.50万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025093203a1e85d90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025093203a1e85d90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1161","01530","BK1583"],"gpt_icon":0},{"id":"2477501731","title":"三生制药(01530.HK)附属公司获得紫杉醇口服溶液内地及香港独家商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2477501731","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477501731?lang=zh_cn&edition=full","pubTime":"2024-10-24 17:35","pubTimestamp":1729762500,"startTime":"0","endTime":"0","summary":"三生制药(01530.HK) 公布，其附属公司沈阳三生制药与上海海和药物及其附属公司诺迈西医药达成《紫杉醇口服溶液独家商业化合作协议》。协议约定，沈阳三生将获得诺迈西医药旗下产品紫杉醇口服溶液于内地及香港独家商业化权利。沈阳三生 将据协议，向诺迈西医药支付首付款以及相应的研发及销售里程碑付款。诺迈西医药将继续负责已开展的III期临床试验及产品后续的开发、临床及注册等工作。(vc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-10-24 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190627151657886_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190627151657886_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1390882/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","BK1161","BK1583","01530"],"gpt_icon":0},{"id":"2477506009","title":"三生制药(01530)：沈阳三生与海和药物就紫杉醇口服溶液达成合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2477506009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477506009?lang=zh_cn&edition=full","pubTime":"2024-10-24 17:29","pubTimestamp":1729762157,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，公司的附属公司沈阳三生制药有限责任公司(沈阳三生)与上海海和药物研究开发股份有限公司(海和药物)及其附属公司诺迈西(上海)医药科技有限公司(诺迈西医药)达成《紫杉醇口服溶液独家商业化合作协议》。协议约定，沈阳三生将获得诺迈西医药旗下产品紫杉醇口服溶液于中国大陆及中国香港地区的独家商业化权利。沈阳三生将根据协议约定，向诺迈西医药支付首付款以及相应的研发及销售里程碑付款。诺迈西医药将继续负责已开展的III期临床试验及产品后续的开发、临床及注册等工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1593","BK1161","BK1583"],"gpt_icon":0},{"id":"2477051374","title":"三生制药10月23日主力资金流出939万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2477051374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477051374?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:15","pubTimestamp":1729671338,"startTime":"0","endTime":"0","summary":"10月23日, 三生制药股价跌0.16%，报收6.29元，成交金额7458万元，换手率0.50%，振幅2.22%，量比1.12。三生制药今日主力资金净流出939万元，连续3日净流出，上一交易日主力净流出896万元，今日环比增加4.80%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为2.70%。该股近5个交易日上涨1.44%，主力资金累计净流出1386万元；近20日主力资金累计净流出2638万元，其中净流出天数为11日。该股主力净额占比0.06%，港股市场排名2594/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102316155895bd353b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102316155895bd353b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","BK1583","BK1161","BK1593"],"gpt_icon":0},{"id":"2477063821","title":"《大行》招银国际：关注创新品种医保机遇  看好药明康德(603259.SH)、百济神州(BGNE.US)、信达生物(01801.HK)、科伦博泰(06990.HK)、巨子生物(02367.HK)、三生制药(01530.HK)和迈瑞医疗(300760.SZ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2477063821","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477063821?lang=zh_cn&edition=full","pubTime":"2024-10-22 10:09","pubTimestamp":1729562940,"startTime":"0","endTime":"0","summary":"招银国际发表研究报告指，MSCI中国医疗指数年初至今累计下跌14.1%，跑输MSCI中国指数31.25%。本轮波动再次体现医药产业的高弹性特质。招银国际认为，宏观经济的表现与健保基金的收支、医疗健康消费息息相关。CXO板块预计将受惠于海外研发需求复苏，《生物安全法案》的影响或将有限。该行关注创新品种医保机遇，看好药明康德、百济神州、信达生物、科伦博泰、巨子生物、三生制药和迈瑞医疗。沽空资料截至 2024-10-21 16:25。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211229100131055_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211229100131055_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1389954&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00B29SXG58.USD","688235","IE00B031J352.USD","LU2125910500.SGD","LU2153591404.USD","LU1146622755.USD","LU2148510915.USD","LU0359202008.SGD","LU2348773727.SGD","603259","BK1593","LU1580142542.USD","LU0572944931.SGD","BK1500","LU0327786744.USD","BK0239","BK1589","LU2153592121.USD","LU0320764599.SGD","IE00B031HY20.USD","LU1688375341.USD","06990","IE0031814852.USD","02359","LU0052750758.USD","06160","LU1720050803.USD","LU0456842615.SGD","LU0405327494.USD","BK0251","LU1781817850.SGD","LU1997245177.USD","300760","LU0084288322.USD","BK1207","01530","LU2488822045.USD","02367","LU0594300419.USD","LU2348774022.SGD","LU0594300179.USD","LU1979443071.USD","LU1655091616.SGD","01801","LU2424517915.HKD","LU1934453819.USD","LU0359201612.USD","LU0307460666.USD","LU2328871848.SGD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2477842166","title":"三生制药气从何来？是固步自封还是冲击百亿市场的王者？","url":"https://stock-news.laohu8.com/highlight/detail?id=2477842166","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477842166?lang=zh_cn&edition=full","pubTime":"2024-10-22 08:29","pubTimestamp":1729556955,"startTime":"0","endTime":"0","summary":"今年以来，资本市场特别是香港市场的打压，再加上美联储降息消息的反反复复，让国内不少生物医药上市企业都憋着一口气。回购，已成了自救的一种集体行动。回购公告中“委屈”的共识是：看好公司发展前景，目前股价低于公司实际价值。和药明生物、石药集团等公司的回购计划比起来，同在港交所上市的三生制药（01530.HK)的气...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/Ozd3g1dCHAKYbk8D3KnxZyZKNb8dOWLQWQUCadA4CNe-EAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Ozd3g1dCHAKYbk8D3KnxZyZKNb8dOWLQWQUCadA4CNe-EAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241022A0189G00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241022A0189G00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1161","BK1593","01530","BK1583"],"gpt_icon":0},{"id":"2477047714","title":"三生制药(01530)出现大手成交500万股，成交价$6.14，涉资3.07千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2477047714","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477047714?lang=zh_cn&edition=full","pubTime":"2024-10-21 09:00","pubTimestamp":1729472400,"startTime":"0","endTime":"0","summary":"[大手成交]三生制药(01530)在上午09:00出现大手成交，成交量为500万，成交价为港币$6.14，涉资3.07千万。至目前为止，股价无升跌，今日最高价为$6.14，而最低价为$6.14，总成交量为500万股，总成交金额港币$3.07千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2410211/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","01530","BK1593","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.029},{"period":"1month","weight":-0.1206},{"period":"3month","weight":-0.1178},{"period":"6month","weight":-0.0626},{"period":"1year","weight":-0.1657},{"period":"ytd","weight":-0.2133}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"三生制药是一家主要从事开发、生产、营销及销售医药产品的投资控股公司。该公司的主要产品包括重组人血小板生成素产品，肿瘤坏死因子α抑制剂产品以及重组人促红素等。产品以特比澳，益赛普，益比奥，以及赛博尔等品牌销售。该公司在国内市场和斯里兰卡、多米尼加共和国及泰国等海外市场销售产品。该公司的子公司包括集思有限公司，香港三生医疗有限公司和沈阳三生制药有限责任公司。该公司通过其子公司还从事项目管理及咨询业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.00277},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.015935},{"month":3,"riseRate":0.777778,"avgChangeRate":0.064866},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.015967},{"month":5,"riseRate":0.666667,"avgChangeRate":0.057469},{"month":6,"riseRate":0.777778,"avgChangeRate":0.012147},{"month":7,"riseRate":0,"avgChangeRate":-0.078897},{"month":8,"riseRate":0.4,"avgChangeRate":-0.006345},{"month":9,"riseRate":0.6,"avgChangeRate":0.027364},{"month":10,"riseRate":0.4,"avgChangeRate":-0.022784},{"month":11,"riseRate":0.7,"avgChangeRate":0.063878},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.037252}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}